Shares of Symbiotec Pharmalab Ltd. gained on Monday, October 26, after brokerage firm Motilal Oswal initiated coverage on the stock indicating an upside of 23%.
The brokerage has initiated a “buy” rating with a target price of ₹1,430 per share.
Motilal Oswal said Symbiotec Pharmalab has evolved from a steroidal active pharmaceutical ingredient (API) manufacturer into an integrated platform spanning API fermentation-led CDMO, and complex injectables, backed by manufacturing investments and backward integration.
It said the company is a leading corticosteroid/hormone API supplier, with a total addressable market (TAM) of $800 million, and is expanding into fermentation-based and high-value complex APIs having TAM of $92 billion and 10.4% compound annual growth rate (CAGR) over the calendar years 2024-2029.
Motilal Oswal said the company is already on a path to provide chemistry and fermentation-based capabilities and capacities as a CDMO platform in precision fermentation, industrial biotechnology and biologics, targeting a TAM of $50 billion. It has invested in building a manufacturing facility to forward integrate into double chamber vials, which not only enables better profitability but also enhances traction in the most heavily regulated market (the US).
Its long-standing customer relationships, regulatory capabilities and contracted business support growth visibility, commercialization of new capacities and higher utilization remain the key execution drivers, the brokerage said.
Symbiotec Pharmalab posted a revenue, EBITDA, PAT CAGR of 15%, 51% and 69% reaching ₹870 crore, ₹240 crore and ₹110 crore, respectively, over FY23-26, Motilal Oswal said.
Motilal Oswal expects the company’s revenue to grow at a 33% CAGR to ₹2,030 crore, EBITDA to also grow at a 33% CAGR to ₹560 crore, and PAT to grow to ₹300 crore over financial year 2026-2029, led by new product launches, scale up of CDMO & injectable operations, and operating leverage.
It values the stock at 35 times its 12-month forward earnings to arrive at its target price, factoring in the company’s established API base and earnings potential from the newer businesses.
Motilal Oswal Bull Case Projects 45% Upside
In a bull-case scenario, Motilal Oswal has a target price of ₹1,690 per share on the stock, an upside of 45%.
It assumes a 12-month forward earnings per share (EPS) of ₹44.5 and assigns a 38x price-to-earnings multiple.
The bull case factors in faster earnings growth, driven by accelerated commercialization of new API and fermentation capacities, stronger traction in CDMO contracts, faster scale-up of complex injectables and improved operating leverage.
Bear Case Scenario Sees Significant Downside
In a bear-case scenario, the brokerage has a target price of ₹1,000 per share.
It assumes a 12-month forward EPS of ₹32.5 and assigns a lower 31x price-to-earnings multiple.
The bear case factors in delayed commercialization of new capacities, slower ramp-up of CDMO and complex injectables, weaker-than-expected API growth, and higher operating costs affecting profitability.
What Are The Key Risks For Symbiotec Pharmalabs?
Motilal Oswal lists the following as key risks for the stock:
- High dependence on APIs and a concentrated product portfolio.
- Delays in scaling CDMO, biologics, complex injectables.
- Geogaphical concentration of manufacturing facilities.
- Intensifying competition.
Stock reaction
Apart of Motilal Oswal, ICICI Direct is the only other analyst that has coverage on the stock, with a “buy” rating and target price of ₹1,540 per share, indicating an upside 32.3% from its previous closing price.
Shares of Symbiotec Pharmalab gained 7.4% to hit an intraday high of ₹1,250.1 apiece on Monday. The stock is currently trading 4.6% higher at ₹1,218.1. The stocks is up 23% from its issue price of ₹988.
Also Read: Apollo Micro shares jump 9% after reiterating growth guidance, exports upside on Q2 results
NOTE TO READERS
Disclaimer: The views and investment tips expressed by investment experts on CNBCTV18.com are their own and not that of the website or its management. CNBCTV18.com advises users to check with certified experts before taking any investment decisions.